Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates

Core Viewpoint - Codexis reported a quarterly loss of $0.13 per share, significantly worse than the Zacks Consensus Estimate of a loss of$0.02, marking an earnings surprise of -550% [1] - The company’s revenues for the quarter were $21.46 million, missing the consensus estimate by 26.65$26.56 million a year ago [2] Financial Performance - Over the last four quarters, Codexis has surpassed consensus EPS estimates only once [2] - The company has topped consensus revenue estimates three times in the last four quarters [2] - Year-to-date, Codexis shares have declined by approximately 12.8%, contrasting with a 1.3% gain in the S&P 500 [3] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [3] - Current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of$13.49 million, and for the current fiscal year, it is -$0.66 on revenues of$65.26 million [7] - The estimate revisions trend for Codexis is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Codexis belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]